Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,471.00    11.00 (0.75%)
Bid:
1,475.00
Ask:
1,477.00
Spread: 2.00 (0.136%)
Market Cap: £3.13b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Dividend Declaration

13 May 2011 14:04

RNS Number : 5844G
Hikma Pharmaceuticals Plc
13 May 2011
 



  

Hikma Pharmaceuticals PLC

Final Dividend for 2010

LONDON, 13 May 2011 - Hikma Pharmaceuticals PLC ("the Company") advises that at its Annual General Meeting of shareholders, held on 12 May 2011, the final dividend of 7.5 cents per share was approved by shareholders. The dividend will be paid on 26 May 2011 to shareholders on the register on 15 April 2011.

Shareholders who have elected to receive their dividend in Pounds Sterling will receive approximately 4.6 pence per Ordinary Share (exchange rate US$1.6278 to GBP£1).

- ENDS -

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Henry Knowles

Company Secretary

 

+44 20 7399 2670

Susan Ringdal

Investor Relations Director

 

+44 20 7399 2670

 

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2010, the Group achieved revenues of $731 million (2009 $637 million) and profit attributable to shareholders was $99 million (2009 $78 million).

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DIVAJMJTMBMBBJB
Date   Source Headline
7th Dec 20169:35 amRNSDirector/PDMR Shareholding
6th Dec 20166:04 pmRNSTotal Voting Rights
5th Dec 201612:34 pmRNSDirector/PDMR Shareholding
2nd Dec 20165:42 pmRNSDirector/PDMR Shareholding
28th Nov 20169:59 amRNSDirector/PDMR Shareholding
22nd Nov 20167:00 amRNSHikma announces agreement with Vectura
16th Nov 201611:12 amRNSAdditional Listing
11th Nov 20162:48 pmRNSTotal Voting Rights
10th Nov 20167:00 amRNSTrading Statement
3rd Oct 20164:37 pmRNSBlock listing Interim Review
28th Sep 20165:12 pmRNSDirector/PDMR Shareholding
28th Sep 20169:09 amRNSDirector/PDMR Shareholding
26th Sep 201610:18 amRNSDirector/PDMR Shareholding
22nd Sep 20163:35 pmRNSDirector/PDMR Shareholding
20th Sep 20167:00 amRNSBoard appointment and succession
16th Sep 20165:32 pmRNSDirector/PDMR Shareholding
15th Sep 20164:36 pmRNSDirector/PDMR Shareholding
8th Sep 20165:18 pmRNSDirector/PDMR Shareholding
6th Sep 20165:52 pmRNSDirector/PDMR Shareholding
6th Sep 20164:02 pmRNSTotal Voting Rights
1st Sep 201610:18 amRNSDirector/PDMR Shareholding
26th Aug 20164:28 pmRNSDirector/PDMR Shareholding
26th Aug 20169:47 amRNSDirector/PDMR Shareholding
24th Aug 20167:00 amRNSHalf-year Report
10th Aug 20169:22 amRNSNotice of Results
3rd Aug 20165:18 pmRNSTrading Statement
21st Jul 20167:00 amRNSRegulatory approval of Hikma's colchicine upheld
20th Jul 20167:00 amRNSLaunch of Generic Xeloda® Tablets in the US
27th Jun 20167:01 amRNSDirector/PDMR Shareholding
27th Jun 20167:00 amRNSTotal Voting Rights
20th Jun 20167:00 amRNSDirector/PDMR Shareholding
7th Jun 20164:44 pmRNSTotal Voting Rights
24th May 20167:00 amRNSDirector/PDMR Shareholding
19th May 201612:15 pmRNSFurther re Colchicine Litigation
19th May 201610:17 amRNSDirector/PDMR Shareholding
18th May 20164:25 pmRNSDirector/PDMR Shareholding
12th May 20163:14 pmRNSResult of AGM
12th May 20167:00 amRNSAGM Statement
9th May 20164:05 pmRNSDirector/PDMR Shareholding
6th May 20169:12 amRNSDoc re. Bond Guarantor Group
29th Apr 20165:40 pmRNSDirector/PDMR Shareholding
28th Apr 20162:58 pmRNSDirector/PDMR Shareholding
25th Apr 20164:19 pmRNSDirector/PDMR Shareholding
22nd Apr 20164:22 pmRNSDirector/PDMR Shareholding
20th Apr 20164:00 pmRNSDirector/PDMR Shareholding
19th Apr 20164:14 pmRNSDirector/PDMR Shareholding
19th Apr 201612:57 pmRNSDirector/PDMR Shareholding
12th Apr 201610:02 amRNSDirector/PDMR Shareholding
8th Apr 20167:00 amRNSUpdate on ANDA for Generic Advair Diskus®
8th Apr 20167:00 amRNSPortfolio Update - VR315 US

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.